RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,673,446 | -0.2% | 349,470 | -2.5% | 0.01% | +16.7% |
Q2 2023 | $2,678,219 | +9.3% | 358,530 | -2.4% | 0.01% | 0.0% |
Q1 2023 | $2,450,491 | -13.5% | 367,390 | 0.0% | 0.01% | -14.3% |
Q4 2022 | $2,832,577 | -27.5% | 367,390 | 0.0% | 0.01% | -36.4% |
Q3 2022 | $3,909,000 | +28.6% | 367,390 | -1.6% | 0.01% | +37.5% |
Q2 2022 | $3,039,000 | +13.7% | 373,390 | 0.0% | 0.01% | +33.3% |
Q1 2022 | $2,673,000 | -58.2% | 373,390 | 0.0% | 0.01% | -53.8% |
Q4 2021 | $6,396,000 | -30.2% | 373,390 | -6.3% | 0.01% | -35.0% |
Q3 2021 | $9,168,000 | – | 398,420 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
Artal Group S.A. | 960,204 | $7,403 | 0.41% |